Search Within

Matthew David Hellmann

Formats
  1. Meeting Abstract (210)
  2. Journal Article (182)
  3. Review (5)
  4. Editorial (4)
  5. Research Letter (3)
  6. Guidelines (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (407)
  2. Solid Tumor Oncology Division (407)
  3. Thoracic Oncology (407)
  4. GSK Faculty (137)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (83)
  6. Melanoma and Immunotherapeutics Service (81)

More Groups

People
  1. Hira Rizvi (95)
  2. Mark Kris (71)
  3. Jamie Chaft (68)
  4. Charles Rudin (65)
  5. Jedd Wolchok (53)
  6. Gregory Riely (48)

More People

Years
  1. 2024 (4)
  2. 2023 (14)
  3. 2022 (34)
  4. 2021 (40)
  5. 2020 (55)
  6. 2019 (62)

More Years

Publications
  1. Journal of Clinical Oncology (90)
  2. Journal of Thoracic Oncology (58)
  3. Annals of Oncology (49)
  4. Journal for ImmunoTherapy of Cancer (30)
  5. Cancer Research (24)
  6. Clinical Cancer Research (19)

More Publications

Publishers
  1. American Society of Clinical Oncology (95)
  2. Elsevier Inc. (75)
  3. American Association for Cancer Research (56)
  4. Oxford University Press (53)
  5. Biomed Central Ltd (30)
  6. Nature Publishing Group (21)

More Publishers

Results (407)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion
    Journal Article

    Shakiba, M.; Zumbo, P.; Espinosa-Carrasco, G.; Menocal, L.; Dündar, F.; Carson, S. E.; Bruno, E. M.; Sanchez-Rivera, F. J.; Lowe, S. W.; Camara, S.; more...
    Journal of Experimental Medicine (2022)

    Fulltext@MSK | Save
  • Insights from prospective multi-omic profiling of lymphocytes in resected lung cancer
    Editorial

    Chow, A.; Hellmann, M. D.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC
    Meeting Abstract

    Hellmann, M.; Cho, B.; Juergens, R.; Cheng, Y.; de Castro, G.; Erman, M.; Bauman, J.; Takahashi, T.; Schwarzenberger, P.; Zhang, P.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Keynote-495/keyimpact: Interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer (Nsclc)
    Meeting Abstract

    Gutierrez, M.; Lam, W. S.; Hellmann, M.; Gubens, M.; Aggarwal, C.; Tan, D. S. W.; Felip, E.; Chiu, J. W. Y.; Lee, J. S.; Yang, J. C. H.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma
    Meeting Abstract

    Zhang, J.; Caushi, J.; Oliveira, G.; Zhang, B.; Ji, Z.; Naidoo, J.; Marrone, K.; Taube, J.; Hellmann, M.; Brahmer, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial
    Meeting Abstract

    Feils, A.; Erbe, A.; Birstler, J.; Kim, K.; Hoch, U.; Currie, S.; Nguyen, T.; Yu, D.; Siefker-Radtke, A.; Tannir, N.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227
    Meeting Abstract

    Schumann, C.; Paz-Ares, L.; Ciuleanu, T. E.; Lee, J. S.; Urban, L.; Caro, R. B.; Park, K.; Sakai, H.; Ohe, Y.; Nishio, M.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1
    Meeting Abstract

    Reck, M.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Bernabe Caro, R.; Linardou, H.; Burgers, J.; Gallardo, C.; Nishio, M.; Peters, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status
    Meeting Abstract

    Ramalingam, S. S.; Balli, D.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Schenker, M.; Caro, R. B.; Lee, K. H.; Bartolucci, R.; Audigier-Valette, C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Phase 3 study of first-line pembrolizumab ± vibostolimab (anti-TIGIT) in patients with PD-L1‒positive metastatic NSCLC
    Meeting Abstract

    Hellmann, M. D.; Cho, B. C.; Juergens, R.; Cheng, Y.; De Castro, G. Jr; Erman, M.; Bauman, J. R.; Takahashi, T.; Schwarzenberger, P.; Zhang, P.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save